Registro:

Referencias:

• Lehnert, M., Clinical multidrug resistance in cancer: A multifactorial problem (1996) Eur. J. Cancer, 32 A (6), pp. 912-920
• O'Brien, J.P., Cordon-Cardo, C., On the origins of clinical drug resistance (1991) Sem. in Cancer Biol., 2 (4), pp. 227-234
• Germann, U.A., P-glycoprotein - A mediator of multidrug resistance in tumour cells (1996) Eur. J. Cancer, 32 A (6), pp. 927-944
• Korsmeyer, S.J., Bcl-2 initiates a new category of oncogenes: Regulators of cell death (1992) Blood, 80 (4), pp. 879-886
• Hickman, J.A., Apoptosis and chemotherapy resistance (1996) Eur. J. Cancer, 32 A (6), pp. 921-926
• Reed, J.C., Bcl-2: Prevention of apoptosis as a mechanism of drug resistance (1995) Hematol/Oncol. Clinics of North Am., 9 (2), pp. 451-470
• Ford, J.M., Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers (1996) Eur. J. Cancer, 32 A (6), pp. 991-1001
• Tilg, G., New insights into the mechanisms of interferon: Alfa: An immunoregulatory and anti-inflammatory cytokine (1997) Gastroenterology, 112, pp. 1017-1021
• Belardelli, F., Gresser, I., The neglected role of type I interferon in the T-cell response: Implications for its clinical use (1996) Immunol. Today, 17 (8), pp. 369-372
• Dexter, D.L., Barbosa, J.A., Calabresi, P.N., N,N-dimetylformamide-induced alteration of cell culture characteristics and loss of tumorigenicity in cultured human colon adenocarcinoma cells (1979) Cancer Res., 39, pp. 1020-1025
• Javad Aman, M., Keller, U., Derigs, G., Mohamadzadeh, M., Huber, C., Peshel, C., Regulation of cytokine expression by interferon-a in human bone marrow stromal cells: Inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist (1994) Blood, 84 (12), pp. 4142-4150
• Keepeers, Y.P., Pizao, P.E., Peters, G.J., Van Akr-Otte, J., Winograd, B., Pinedo, H.M., Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing (1991) Eur. J. Cancer, 27 (7), pp. 897-900
• Arceci, R.J., Stieglitz, K., Bras, J., Schinkel, A., Baas, F., Croop, J., Monoclonal antibody to an external epitope of the human mdr-1 P-glycoprotein (1993) Cancer Res, 53, pp. 310-317
• Broxterman, H.J., Lankelma, J., Pinedo, H.M., How to probe clinical tumor samples for P-glycoprotein and multidrug resistance-associated protein (1996) Eur. J. Cancer, 32 A (6), pp. 1024-1033
• Jiang, M.C., Yang-Yen, H.F., Lin, J.K., Young-Yen, J., Differential regulation of p53, Bcl-2 and Bax protein expression during apoptosis induced by widely divergent stimuli in human hepatoblastoma cells (1996) Oncogene, 13, pp. 609-616
• Miyoshi, T., Ogawa, S., Kanamori, T., Nobuhara, M., Namba, M., Interferon potentiates cytotoxic effects of 5-fluorouracil on cell proliferation of established human cell lines originating from neoplastic tissues (1983) Cancer Letters, 17, pp. 239-247
• Van der Wilt, C.L., Smid, K., Aherne, G.W., Noorhuis, P., Peters, G.J., Biochemical mechanisms of interferon modulation of 5-fluorouracil activity in colon cancer cells (1997) Eur. J. Cancer, 33 (3), pp. 471-478
• Okamoto, E., Kinne, R.K.H., Sokel, J., Interferons modify in vitro proliferation of human bladder transitional cell carcinoma in the presence of doxorubicin and mitomycin C (1996) J. Urol., 156, pp. 1492-1495
• Goto, I., Yamamoto-Yamaguchi, Y., Honma, Y., Enhacement of sensitivity of lung adenocarcinoma cells to growth-inhibitory activity of interferon a by differenciation-inducing agents (1996) Br. J. Cancer, 74, pp. 546-554
• Lindner, D.J., Borden, E.C., Synergistic antitumor effects of a combination of interferon and tamoxifen on estrogen receptor-positive and receptor-negative human tumor cell lines in vivo and in vitro (1997) J. Interferon Cytokine Res., 17, pp. 681-693
• Wadler, S., Schwartz, E.L., Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review (1990) Cancer Res., 50, pp. 3473-3486
• Seliger, B., Hohne, A., Knuth, A., Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression (1996) Clin. Cancer Res., 2, pp. 1427-1433
• Efferth, T., Lohrke, H., Volm, M., Correlations between natural resistance to doxorubicin, proliferative activity and expression of P-glycoprotein 170 in human kidney tumor cell lines (1990) Urol. Res., 18, pp. 309-312
• Fogler, W.F., Pearson, J.W., Volker, K., Enhacement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody (1995) J.N.C.I., 87 (2), pp. 94-103
• Dufour, P., Feugeas, O., Bergerat, J.P., Oberling, F., Etude de la modulation par l'interferon alpha et/ou l'ácide tout transretinoique de la cytotoxicité de l'adriamycine sur le cellules K 562 et K 562 adri (1994) Bull. Cancer, 81, pp. 894-896
• Scala, S., Pacelli, R., Iaffaioli, R.V., Reversal of adriamycin resistance by recombinant a-interferon in multidrug-resistant human colon carcinoma LoVo-doxorubicin cells (1991) Cancer Res., 51, pp. 4898-4902
• Lucero Gritti, M.F., Beviacqua, M., Sánchez, A.M., Bordenave, R.H., Rumi, L.S., Disminución de la expresión de la glicoproteína P-170 por el tratamiento combinado interferón-α2b/ vincristina sobre una línea celular resistente a multidroga. Nuevas Tendencias en Oncologia (1998) Revista Latinoamericana de la European School of Oncology, 7 (1), p. 56
• Kang, Y., Perry, R.R., Effect of alpha-interferon on P-glycoprotein expression and function and on verapamil modulation of doxorubicin resistance (1994) Cancer Res., 54 (11), pp. 2952-2958
• Chin, K.V., Ueda, K., Pastan, Y., Gottesmann, M.M., Modulation of activity of the promoter of the human MDR1 gene by Ras and p53 (1992) Science, 255, pp. 459-462
• Sinicrope, F.A., Roddey, G., McDonell, T.J., Shen, Y., Cleary, K.R., Stephens, L.V., Increased apoptosis accompanies neoplastic development in the human colorectum (1996) Clin. Cancer Res., 2, pp. 1999-2006
• Bonetti, A., Zaninelli, M., Leone, R., Bcl- 2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer (1998) Clin. Cancer Res., 4, pp. 2331-2336
• Fisher, D.E., Apoptosis in cancer therapy: Crossing the threshold (1994) Cell, 78, pp. 539-542
• Muller, M., Strand, S., Hug, H., Heinemann, E.M., Walczak, H., Hofmann, W., Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO/Fas) receptor/ligand system and involves activation of wild-type p53 (1997) J. Clin. Invest., 99, pp. 403-413
• Yanagihara, K., Ito, A., Toge, T., Numoto, M., Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract (1993) Cancer Res., 53, pp. 5815-5821
• Blagosklonny, M.V., Robey, R., Bates, S., Fojo, T., Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs (2000) J. Clin. Invest., 105 (4), pp. 533-539
• Liu, Q.Y., Stein, C.A., Taxol and estramusine-induced modulation of human prostate cancer cells apoptosis via alteration in bcl-xl and bak expresion (1997) Clin. Cancer Res., 3, pp. 2039-2046
• Bong Lee, S., Rodríguez, D., Rodríguez, J.R., Esteban, M., The apoptosis pathway triggered by the interferon-induced protein kinase PKR requires the third basic domain, initiates upstream of Bcl-2 and involves 1CE-like proteases (1997) Virology, 231, pp. 81-88

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------